THIAZOVIVIN性質、用途與生產工藝

生物活性

Thiazovivin是一種新型ROCK抑制劑，IC50為0.5 μM，在單細胞分離后，促進人胚胎干細胞（hESC）的存活。

體外研究

Although displaying little impact on cell proliferation, Thiazovivin treatment significantly enhances the survival of human embryonic stem cells (hESCs) after enzymatic dissociation more than 30-fold, while homogenously maintaining pluripotency with the characteristic colony morphology, expression of typical pluripotency markers such as alkaline phosphatase (ALP), and normal karyotype. Dissociated hESCs treated with Thiazovivin display dramatically increased adhesion to matrigel- or laminin-coated plates but not to gelatin-coated plates within a few hours. Thiazovivin treatment increases cell-ECM adhesion-mediated β1 integrin activity, which synergizes with growth factors to promote cell survival. In addition to activating integrin, Thiazovivin but not Tyrintegin (Ptn) protects hESCs from death in the absence of ECM in suspension through E-cadherin-mediated cell-cell interaction. Thiazovivin treatment potently inhibits endocytosis of E-cadherin, consequently stabilizing E-cadherin on the cell surface and leading to reestablishment of cell-cell interaction, which is essential for hESC survival in ECM-free conditions. Thiazovivin but not Tyrintegin (Ptn) at 2 μM inhibits Rho-associated kinase (ROCK) activity and protects hESCs at a similar level as the widely used selective ROCK inhibitor Y-27632 at 10 μM, suggesting that Rho-ROCK signaling regulates cell-ECM and cell-cell adhesion. Thiazovivin at 1 μM increases the reprogramming efficiency of CB mononuclear cells to induced pluripotent stem cells (iPSCs) by more than 10 times.

生物活性

Thiazovivin是一種新型ROCK抑制劑，無細胞試驗中IC50為0.5 μM，在單細胞分離后，促進人胚胎干細胞（hESC）的存活。

靶點

Target	Value
ROCK (Cell-free assay)	~0.5 μM

體外研究

盡管對細胞增殖影響較小，Thiazovivin治療顯著增強人胚胎干細胞(hESCs)的存活，使其被酶解后的存活增強30多倍，同時均勻維持特有集落形態(tài)的多潛能，和典型多潛能標志物，如堿性磷酸酶(ALP) 的表達，和正常核型。解離的hESCs用Thiazovivin處理幾小時內顯著增加其對人工基底膜-或層粘連蛋白涂覆板的粘附，而對明膠涂覆的平板沒有影響。Thiazovivin治療增加細胞-ECM粘附介導的β1整合蛋白活性，其與生長因子協(xié)同促進細胞存活。除了活化整合蛋白，Thiazovivin，而不是Tyrintegin (Ptn)，也能夠通過E-鈣黏蛋白介導的細胞-細胞相互作用，保護hESCs在ECM缺乏的懸浮液中免于死亡。Thiazovivin治療有效抑制E-鈣黏蛋白的內吞作用，從而穩(wěn)定細胞表面的E-鈣黏蛋白，并使細胞-細胞相互作用恢復，這對hESC在無ECM環(huán)境下的存活是必須的。Thiazovivin，而不是Tyrintegin (Ptn)，在2 μM濃度下抑制Rho相關的激酶(ROCK)活性，并保護hESCs，與廣泛使用的選擇性ROCK抑制劑Y-27632在10 μM濃度下的作用類似，表明Rho-ROCK信號調節(jié)細胞-ECM和細胞-細胞粘附。1 μM Thiazovivin增加CB單核細胞的重組效能，以誘導10倍以上的多功能干細胞(iPSCs)。

THIAZOVIVIN 上下游產品信息

上游原料

下游產品

THIAZOVIVIN 試劑級價格

更新日期	產品編號	產品名稱	CAS編號	包裝	價格
2025/02/08	HY-13257	Thiazovivin	1226056-71-8	1 mg	363元
2025/02/08	HY-13257	THIAZOVIVIN Thiazovivin	1226056-71-8	5mg	800元

THIAZOVIVIN 生產廠家

 

1226056-71-8, THIAZOVIVIN 相關搜索:

• Sulfur & Selenium Compounds
• Pharmaceuticals
• Intermediates & Fine Chemicals
• Heterocycles
• Aromatics
• Inhibitors
• 化學試劑
• 高純試劑
• 化工試劑
• 生物試劑
• 藥靶配體
• 原料藥及中間體
• 抑制劑
• 細胞生物學試劑
• 小分子抑制劑
• 雜環(huán)化合物
• 氨基酸衍生化合物
• 小分子抑制劑，天然產物
• 細胞周期
• 226056-71-8
• 化合物THIAZOVIVIN,10 MM DMSO 溶液
• THIAZOVIVIN (DMSO SOLUTION),RHO KINASE抑制劑
• THIAZOVIVIN,ROCK抑制劑
• 化合物 THIAZOVIVIN
• THIAZOVIVIN,RHO激酶抑制劑
• N-芐基-2-(嘧啶-4-基氨基)噻唑-4-酰胺
• 化合物PNU 74654
• N-芐基2-(嘧啶-4-胺基)噻唑-4-甲酰胺
• ROCK抑制劑(THIAZOVIVIN)
• N-芐基-2-(嘧啶-4-基氨基)噻唑-4-羧酰胺
• N-芐基-2-(嘧啶-4-基氨基)噻唑-4-甲酰胺
• 1226056-71-8
• Thiazovivin, 10 mM in DMSO
• Thiazovivin, ROCK inhibitor
• Thiazovivin (DMSO solution), Rho kinase inhibitor
• TZV
• Thiazovivin USP/EP/BP
• 4-Thiazolecarboxamide, N-(phenylmethyl)-2-(4-pyrimidinylamino)-
• Thiazovivin (Tzv)
• CS-1925
• N-Benzyl-2-(4-pyrimidinylamino)-1,3-thiazole-4-carboxamide
• N-(Phenylmethyl)-2-(4-pyrimidinylamino)-4-thiazolecarboxamide
• Thiazovivin
• N-Benzyl-2-(pyrimidin-4-ylamino)thiazole-4-carboxamide
• Thiazovivin, >=98%
• Thiazovivin N-(Phenylmethyl)-2-(4-pyrimidinylamino)-4-thiazolecarboxamide
• N-(Phenylmethyl)-2-(4-pyrimidinylamino)-4-thiazolecarboxamide Thiazovivin